Screener
CytomX Therapeutics CTMX EPS (Diluted)
Discontinued — last reported Q2 '26
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Unrealized gain (loss) on investments, net of tax | (298) | 34 | (307) | 6 |
| Total comprehensive income (loss) | $(20,964) | $(120) | $(39,221) | $23,377 |
| Net income (loss) per share: | ||||
| Basic | $(0.09) | $(0.00) | $(0.20) | $0.22 |
| Diluted | $(0.09) | $(0.00) | $(0.20) | $0.21 |
| Shares used to compute net income (loss) per share | ||||
| Basic | 218,939,423 | 129,075,546 | 198,221,312 | 108,214,373 |
| Diluted | 218,939,423 | 129,075,546 | 198,221,312 | 108,928,284 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is CytomX Therapeutics's EPS (diluted)?
- CytomX Therapeutics (CTMX) reported EPS (diluted) of -$0.09 in Q2 2026.
- What is the long-term trend for CytomX Therapeutics's EPS (diluted)?
- Over 3 years (2021 to 2025), CytomX Therapeutics's EPS (diluted) has grown at a -71.9% compound annual growth rate (CAGR), from -$1.80 to -$0.04.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about CytomX Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude